Hat-tip to an anonymous commenter, below -- but the UK-based Reckitt doesn't seem to be a likely deal candidate, if FT's sources are to be believed. Here's the snippet from the online London version of Financial Times, which would suggest that Reckitt is not seriously interested in these legacy-Schering's Consumer Health Care assets:
. . . .However, there was some skepticism around Reckitt acquiring Schering Plough’s OTC, two of the industry bankers said. The third banker said he personally did not believe Schering’s OTC unit was the greatest asset, due to products such as OTC allergy medication Claritin, which has reported declining sales. He did, however, mention that Dr. Scholl's foot care products was one of the few strong businesses in the portfolio. . . .
Thus my recurring graphic, at right. We shall see.